FDA Approved: TRIJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TRIJARDY XR, a fixed-dose combination tablet of empagliflozin, linagliptin, and metformin hydrochloride, for adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Linagliptin (linagliptin)
• METFORMIN HYDROCHLORIDE (Metformin hydrochloride)

Snippet

SUPPL AP for TRIJARDY XR (EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE)